Sugi Predict

Sugi Predict / Compounds / SCHEMBL38535

SCHEMBL38535

SCHEMBL38535

Cc1cccc(C)c1C[C@H](N)C(=O)O

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ SLC7A5 Q01650 5/20 0.55
▸ ALPI P09923 1/20 0.55
▸ PKM P14618 1/20 0.55
▸ PTGS1 P23219 1/20 0.55
▸ XIAP P98170 1/20 0.55
▸ NOS3 P29474 2/20 0.47
▸ NOS1 P29475 2/20 0.47
▸ NOS2 P35228 2/20 0.47
▸ GRIA1 P42261 4/20 0.47
▸ GRIA3 P42263 4/20 0.47
▸ GRIA2 P42262 4/20 0.47
▸ GRIA4 P48058 3/20 0.47
▸ MAPT P10636 2/20 0.47
▸ GRIK1 P39086 2/20 0.47
▸ GRIK5 Q16478 2/20 0.47
▸ CYP1A2 P05177 2/20 0.47
▸ MEN1 O00255 1/20 0.47
▸ ALDH1A1 P00352 1/20 0.47
▸ CYP2D6 P10635 1/20 0.47
▸ CYP2C9 P11712 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19667341 1.00 SLC7A5 (0.55) SLC7A5ALPIPKMPTGS1XIAP
SCHEMBL2703289 1.00 SLC7A5 (0.55) SLC7A5ALPIPKMPTGS1XIAP
Hydrochloric Acid SCHEMBL10477485 0.98 SLC7A5 (0.53) SLC7A5ALPIPKMPTGS1XIAP
Hydrochloric Acid SCHEMBL10477486 0.98 SLC7A5 (0.53) SLC7A5ALPIPKMPTGS1XIAP
Phenylalanine SCHEMBL15966897 0.92 SLC7A5 (0.71) SLC7A5ALPIPKMPTGS1XIAP
SCHEMBL38803 0.90 SLC7A5 (0.49) SLC7A5ALPIPKMPTGS1XIAP
SCHEMBL38804 0.90 SLC7A5 (0.49) SLC7A5ALPIPKMPTGS1XIAP
SCHEMBL20889265 0.88 SLC7A5 (0.47) SLC7A5ALPIPKMPTGS1XIAP
SCHEMBL22864320 0.85 SLC7A5 (0.41) SLC7A5ALPIPKMPTGS1XIAP
SCHEMBL7774176 0.84 SLC7A5 (0.44) SLC7A5ALPIPKMPTGS1XIAP

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 625 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2025044786-A1 PEPTIDES, DERIVATIVES THEREOF, AND USE OF SAME 南京医科大学 2025-03-06 — — WO claimed
EP-3464324-B1 ANGIOTENSIN-1-RECEPTOR ANTAGONISTS FERRING BV (NL) 2021-04-07 — — EP claimed
US-20200102348-A1 ANGIOTENSIN-1-RECEPTOR ANTAGONISTS FERRING B.V. (NL) 2020-04-02 — — US claimed
US-10344054-B2 Angiotensin-1-receptor antagonists FERRING B.V. (NL) 2019-07-09 — — US claimed
EP-3061753-B1 ENANTIO-SELECTIVE SYNTHESIS OF NON-NATURAL AMINO ACIDS UNIV DEGLI STUDI G DANNUNZIO CHIETI PESCARA (IT) 2018-08-22 — — EP claimed
US-20170349629-A1 Angiotensin-1-Receptor Antagonists FERRING B.V. (NL) 2017-12-07 — — US claimed
EP-3061753-A1 ENANTIO-SELECTIVE SYNTHESIS OF NON-NATURAL AMINO ACIDS Universita' Degli Studi "G. d'Annunzio" Chieti-Pescara (IT) 2016-08-31 — — EP claimed
JP-4838114-B2 — — 2011-12-14 — — JP claimed
EP-2241306-A2 Compound with antioxidant peptides Henkel AG & Co. KGaA (DE) 2010-10-20 — — EP claimed
EP-2036918-A1 PEPTIDE DERIVATIVE Vexon, Inc. (JP) 2009-03-18 — — EP claimed
US-20080009448-A1 Peptide Derivative VEXON, INC. (50%) (JP) 2008-01-10 — — US claimed
US-20070027087-A1 METHODS FOR PREVENTING MITOCHONDRIAL PERMEABILITY TRANSITION NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT 2007-02-01 — — US claimed
EP-1722807-A2 METHODS FOR REDUCING OXIDATIVE DAMAGE Cornell Research Foundation Inc. (US) 2006-11-22 — — EP claimed
US-20060084606-A1 administering aromatic cationic peptide for specifically target mitochondria; ischemia is due to stroke, sepsis, inflammatory process, arthritis, diabetes, liver disorders, viral infection, to a removed organ CORNELL RESEARCH FOUNDATION, INC. 2006-04-20 — — US claimed
EP-1599216-A2 METHODS FOR PREVENTING MITOCHONDRIAL PERMEABILITY TRANSITION CORNELL RESEARCH FOUNDATION, INC. (US) 2005-11-30 — — EP claimed
WO-2005072295-A2 METHODS FOR REDUCING OXIDATIVE DAMAGE CORNELL RESEARCH FOUNDATION, INC. (US) 2005-08-11 — — WO claimed
US-20040248808-A1 Methods for preventing mitochondrial permeability transition PUBLIC HEALTH SERVICE/NATIONAL INSTITUTES OF HEALTH (NIH) 2004-12-09 — — US claimed
WO-2004070054-A2 METHODS FOR PREVENTING MITOCHONDRIAL PERMEABILITY TRANSITION CORNELL RESEARCH FOUNDATION, INC. (US) 2004-08-19 — — WO claimed
US-20250276116-A1 METHODS OF MITIGATING MYOCARDIAL DAMAGE DUE TO EXTRACORPOREAL MEMBRANE OXYGENATION TUFTS MEDICAL CENTER, INC. 2025-09-04 — — US disclosed
US-4879398-A Process for producing 2,6-disubstituted tyrosine MONSANTO COMPANY (US) 1989-11-07 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20170349629-A1 Angiotensin-1-Receptor Antagonists AGTR1, AGTR2, REN SLC7A5 289/4885ALPI 3555/4885PKM 3664/4885
US-20200102348-A1 ANGIOTENSIN-1-RECEPTOR ANTAGONISTS AGTR1, AGTR2, REN SLC7A5 289/4885ALPI 3555/4885PKM 3664/4885
US-10344054-B2 Angiotensin-1-receptor antagonists AGTR1, AGTR2, AGT SLC7A5 392/4885ALPI 3362/4885PKM 3198/4885
US-20080009448-A1 Peptide Derivative ARGLU1, NGLY1, NPR3 SLC7A5 221/4885ALPI 4171/4885PKM 2599/4885
US-20250276116-A1 METHODS OF MITIGATING MYOCARDIAL DAMAGE DUE TO EXTRACORPOREAL MEMBRANE OXYGENATION TNNI3, TNNT2, MB SLC7A5 4605/4885ALPI 466/4885PKM 616/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.